Canagliflozin, sold under the brand name Invokana among others, is a medication used to treat type 2 diabetes. It is used together with exercise and diet. It is not recommended in type 1 diabetes.[1] See also Canagliflozin.
Canagliflozin is an inhibitor of subtype 2 Sodium/glucose cotransporter (SGLT2), which is responsible for at least 90% of renal glucose reabsorption (the remaining 10% is done by SGLT1). Blocking this transporter causes up to 119 grams of blood glucose per day to be eliminated through the urine,[2] corresponding to 476 kilocalories. Additional water is eliminated by osmotic diuresis, resulting in a lowering of blood pressure.
Canagliflozin also inhibits renal SGLT1, contributing to about 10% of daily urinary glucose excretion.[3][4]
This mechanism is associated with a low risk of hypoglycaemia (too low blood glucose) compared to other types of anti-diabetic drugs such as sulfonylurea derivatives and insulin.[5]
(8hdh).
.
See also:
